Fisetin: The Senolytic Flavonoid, and What the Evidence Says
Explore the clinic directoryIn this article
Fisetin is a flavonol found in strawberries, apples and onions that was the most potent senolytic in a panel of flavonoids tested by Yousefzadeh and colleagues (EBioMedicine, 2018), and it extended healthspan and lifespan in aged mice [2]. In people the evidence is early: the Mayo Clinic AFFIRM trials are testing 20 mg/kg/day for two consecutive days against placebo for frailty and inflammation, and no human dose has been validated [4][5].
That gap between strong animal data and thin human data is the whole story. Trials are running, published results are limited, and the best dose is unknown.
Next step: Use the Directory to browse vetted clinics while you research senolytic options like fisetin.
Key Takeaways
- Fisetin (3,3′,4′,7-tetrahydroxyflavone) is a dietary flavonol with antioxidant and anti-inflammatory activity, concentrated in strawberries, according to Khan and colleagues (2013) [1].
- The hype comes from strong mouse data: Yousefzadeh and colleagues (2018) found fisetin acts as a senolytic, clearing senescent cells and extending median and maximum lifespan in aged mice [2].
- Human trials (the Mayo Clinic AFFIRM program, two Phase 2 placebo-controlled studies registered on ClinicalTrials.gov) are testing frailty and inflammation endpoints, and no results have been posted yet [4][5].
- Two dosing camps circulate online: high-dose “hit-and-run” intermittent protocols near 20 mg/kg for two days, and low-dose daily supplements of 100 to 500 mg. Neither is validated for humans.
- Evidence grade: Early. Mechanistic plus strong animal data, thin human data. Verdict: biologically promising, not yet shown to work in people.
What is fisetin?
Fisetin is a flavonol, a subclass of plant flavonoids. It gives some fruits and vegetables their color and acts as a natural antioxidant. Dietary sources include strawberries (the richest common source), apples, persimmons, grapes, onions, and cucumbers. Typical daily intake from food is small, in the low milligram range, far below the doses used in laboratory studies.
Chemically, fisetin is closely related to quercetin, another flavonol studied for senolytic activity. For decades fisetin was studied mainly as a general antioxidant and anti-inflammatory compound, with signals in neuroprotection and metabolic health from cell and animal work [1][6]. Its current fame rests on something newer: its behavior as a senolytic.
In the United States fisetin is sold as a dietary supplement, usually in capsules. The FDA regulates supplements under different rules from drugs: according to the FDA’s dietary supplement guidance, products do not need agency approval for safety or effectiveness before they are sold. Fisetin is not an approved treatment for any condition, and label strength and purity vary between products.
Why is fisetin getting so much attention?
Answer first: because a 2018 mouse study found fisetin was the most potent senolytic among a panel of flavonoids, and giving it to already-aged mice extended their healthspan and lifespan [2].
Senescent cells are cells that have stopped dividing but refuse to die. They accumulate with age and secrete a mix of inflammatory signals known as the senescence-associated secretory phenotype, or SASP. This low-grade inflammation is linked to many age-related conditions. A senolytic is a compound that selectively kills these cells. Earlier work identified fisetin among agents that target senescent cells [3], and the 2018 study went further by showing whole-animal benefits: reduced senescence markers across tissues, lower inflammation, and longer life even when treatment started late [2].
That combination, a cheap dietary molecule with a clear mechanism and dramatic animal results, is what fuels the interest.
How does fisetin work as a senolytic?
Fisetin appears to push senescent cells into apoptosis, the programmed cell death they normally resist. Senescent cells survive by switching on pro-survival pathways, sometimes called senescent cell anti-apoptotic pathways. Senolytics work by temporarily disabling those defenses, which leaves healthy cells largely unaffected.
The effect depends on cell type. Zhu and colleagues at Mayo Clinic (Aging, 2017) found fisetin selectively killed senescent human endothelial cells but not senescent human preadipocytes, a fat cell precursor [3]. That selectivity is one reason researchers test senolytics in combinations and in specific tissues rather than assuming one compound clears every senescent cell.
Who are the researchers behind senolytics?
The senolytic field grew largely out of work by James Kirkland and Tamara Tchkonia at Mayo Clinic, whose group published the 2017 fisetin paper [3]. Mayo Clinic also sponsors the AFFIRM trials [4][5]. The 2018 lifespan study came from a team including Matthew Yousefzadeh, Paul Robbins and Laura Niedernhofer [2]. Their animal results are the reference point every human fisetin protocol is built on.
What does the human evidence actually show?
Answer first: very little so far. The human story is mostly ongoing trials, not finished results.
The Mayo Clinic has run the AFFIRM program, short for Alleviation by Fisetin of Frailty, Inflammation, and Related Measures. These trials test intermittent fisetin in older adults and look at frailty, physical function, and inflammatory markers rather than lifespan [4][5]. As of July 24, 2026, this early-phase work has not produced large, published, peer-reviewed efficacy results that confirm the mouse findings translate to people.
The registry entries spell out the design. Both studies are Phase 2, placebo controlled, and list an estimated enrollment of 40 participants each. The study in older women (NCT03430037) gives fisetin at 20 mg/kg/day for two consecutive days, repeated over two months. The study in older adults (NCT03675724) uses the same two-day course. Both began in 2018, both were enrolling by invitation when last updated in May 2026, and neither had posted results.
Fisetin is also being explored in neurodegeneration, where preclinical data are encouraging but clinical application remains early [6]. The honest summary: the mechanism is plausible, the animal data are strong, and the human data are thin and still coming in.
| Evidence type | What it shows | Strength |
|---|---|---|
| Mechanistic / cell studies | Selective killing of senescent cells, antioxidant and anti-inflammatory effects [1][3] | Strong |
| Animal (aged mice) | Reduced senescence markers, extended healthspan and lifespan [2] | Strong |
| Human trials | Frailty and inflammation endpoints under study; results limited or pending [4][5] | Early / thin |
| Long-term human safety | Not established at high supplement doses | Unknown |
Which conditions is fisetin being studied for?
Fisetin is studied for age-related decline rather than for one disease. The AFFIRM trials measure frailty, physical function and inflammatory markers in older adults [4][5]. Preclinical work extends to neurodegeneration, including models of cognitive decline [6].
Senescent cells also build up in joint cartilage, which is why osteoarthritis is one of the conditions researchers have looked at for senolytic approaches. The same idea draws interest from people managing chronic inflammation. For both, fisetin remains an experimental idea, not an established therapy, and standard care for those conditions comes first.
What is the difference between hit-and-run dosing and daily supplements?
Answer first: they are two very different strategies, and neither has a proven human dose.
The “hit-and-run” approach mirrors the animal trials. Senolytics are often given in short, high-dose bursts on the theory that you only need to knock out senescent cells periodically, then stop, letting the body clear the debris. Protocols circulating online typically cite around 20 mg/kg per day for two consecutive days, repeated every few weeks or months. For a 70 kg adult that is roughly 1,400 mg per day, a large dose taken briefly.
The low-dose daily approach instead uses smaller amounts, often 100 to 500 mg, taken continuously like a routine supplement. This is closer to how many flavonoid supplements are marketed, but it does not match the intermittent, high-exposure design that produced the mouse benefits.
The key point: the optimal human dose, schedule, and even whether either strategy works in people are unknown. Online protocols are extrapolated from animals and self-experimenters, not established by clinical outcomes.
| Approach | Typical amount | Schedule | Where it comes from |
|---|---|---|---|
| Hit-and-run (intermittent) | About 20 mg/kg per day, roughly 1,400 mg for a 70 kg adult | Two consecutive days, repeated every few weeks or months | Animal studies and the registered AFFIRM trial design [2][4][5] |
| Low-dose daily | 100 to 500 mg | Every day, like a routine supplement | Supplement marketing and self-experimenters |
| Diet only | A few milligrams | Daily, from strawberries, apples and onions | Normal food intake [1] |
Why does the 20 mg/kg figure keep coming up?
The 20 mg/kg per day, two-day course is the dose Mayo Clinic registered for both AFFIRM trials on ClinicalTrials.gov [4][5]. A dose being tested in a trial is not the same as a dose shown to work. Until those trials report, the figure describes a research protocol, not a recommendation.
What about bioavailability and safety?
Answer first: fisetin is poorly absorbed and cleared quickly, and while short-term use looks reasonably tolerated, long-term high-dose safety is not established.
Fisetin has low oral bioavailability. It is not very water soluble, is metabolized rapidly, and reaches only modest blood levels after ingestion. This is a central reason high doses are used in research and why some supplements add absorption enhancers or use liposomal or nano-formulations to try to raise uptake. How well these formulations improve real-world outcomes in humans is not yet clear.
On safety, fisetin has a long history as a food component and short-term study doses have generally been tolerated. But supplement-level doses far exceed dietary intake, long-term data are missing, and flavonoids can interact with drug-metabolizing enzymes and blood thinners. Anyone on medication, pregnant, or managing a health condition should treat high-dose fisetin as an experimental compound and talk to a clinician first.
Who should avoid fisetin or check with a clinician first?
People taking prescription medication carry the clearest risk, because flavonoids can change how the liver’s drug-metabolizing enzymes handle other drugs. Blood thinners deserve particular caution. A pharmacist can check a medication list for likely interactions.
- People who are pregnant or breastfeeding, since no safety data exist for high-dose fisetin in pregnancy.
- People on anticoagulant or antiplatelet drugs, or with an upcoming surgery.
- People with liver or kidney disease, which can change how the body clears flavonoids.
- People receiving cancer treatment, where any compound that affects cell death pathways should be cleared with the oncology team.
- Anyone expecting fisetin to treat a diagnosed condition, since no human trial has shown that it does.
Primary care physicians, geriatricians and pharmacists can all help weigh these questions. Physicians who practice integrative or longevity medicine are more likely to discuss senolytics directly, but the evidence they work from is the same thin human evidence described above.
How does fisetin compare to other senolytics?
Fisetin sits alongside a small group of compounds studied for clearing senescent cells. The most cited pharmaceutical pairing is dasatinib and quercetin, a prescription drug plus a flavonoid combination tested in early human senolytic trials. Fisetin is attractive because it is a single, food-derived molecule with a strong animal signal, but it shares the field’s core limitation: human proof is still forming. For the wider landscape, see our guides on senolytics and anti-aging supplements linked below.
| Compound | What it is | How it is obtained | Human evidence |
|---|---|---|---|
| Fisetin | Dietary flavonol, single molecule | Over the counter as a dietary supplement | Phase 2 trials under way, no posted results [4][5] |
| Dasatinib plus quercetin (D+Q) | Cancer drug paired with a flavonol | Dasatinib needs a prescription; its use as a senolytic is off label | Small early human pilot studies |
| Quercetin alone | Dietary flavonol closely related to fisetin | Over the counter as a dietary supplement | Studied mainly as part of D+Q |
Senolytics are one part of a broader longevity toolkit. Other approaches people research include rapamycin for longevity and NAD+ precursors, which work through different pathways and carry their own evidence questions.
Do clinics offer fisetin or senolytic therapy?
Some longevity and integrative medicine clinics include senolytic protocols in their programs, usually alongside other services. Fisetin itself is an oral supplement, so a clinic visit adds medical oversight, lab work and an interaction review rather than a different product. Services you may see offered next to senolytics include NAD+ IV therapy and peptide therapy, both cash pay and both with limited evidence for anti-aging uses.
If you want a supervised approach, you can browse clinics that offer NAD+ IV therapy or compare peptide therapy providers and ask each one how they handle senolytic protocols. Good questions include which dose and schedule they use, what evidence they cite, which labs they check before and after, and how they screen for drug interactions.
Listing order in the directory is not paid ranking. Featured slots are labeled and capped. Verified means credential checks, not spend. Regenerated.com is free for patients. Inclusion in the directory is not an endorsement. How Featured, Verified and organic listings differ explains each label.
Frequently asked questions
Can I get enough fisetin from food to clear senescent cells?
No. Strawberries are the richest common source of fisetin, but even a large serving delivers only a few milligrams. The senolytic effects seen in aged mice used doses hundreds of times higher than any realistic diet [2]. Eating strawberries, apples and onions is healthy and adds other flavonoids, but it will not replicate the doses used in research or in online hit-and-run protocols.
Has fisetin been shown to extend human lifespan?
No. The lifespan and healthspan extension was shown in aged mice, not humans [2]. Human trials so far focus on frailty and inflammation markers, and their results are limited or still pending [4][5]. As of July 24, 2026 there is no clinical evidence that fisetin extends human lifespan, and neither Mayo Clinic AFFIRM trial had posted results on ClinicalTrials.gov at its last update.
What dose of fisetin do people take?
It varies and none is validated. High-dose “hit-and-run” users cite around 20 mg/kg for two days, repeated periodically, mimicking animal studies and the AFFIRM trial design [4][5]. Daily-supplement users take 100 to 500 mg. The optimal human dose and schedule are unknown, so any figure online is an estimate, not an evidence-based recommendation, and a clinician should review it against your medications.
Is fisetin safe to take as a supplement?
Short-term use at study doses appears reasonably tolerated, but long-term high-dose safety is not established. Fisetin can interact with drug-metabolizing enzymes and blood thinners, and supplement doses far exceed dietary intake. If you take medication, are pregnant, or have a health condition, consult a clinician before using high-dose fisetin, and remember that supplements are not FDA approved for safety before sale.
Is fisetin better than quercetin as a senolytic?
Fisetin was the most potent senolytic in the 2018 flavonoid panel by Yousefzadeh and colleagues, which tested it alongside related compounds including quercetin [2]. Quercetin is mainly studied paired with the drug dasatinib rather than alone. Neither flavonol has human outcome data showing it clears senescent cells better than the other, so the comparison rests on cell and mouse work.
Can a doctor prescribe fisetin?
Fisetin is sold over the counter as a dietary supplement, so it does not need a prescription. A physician can still supervise its use, choose a dose, order baseline labs and check for drug interactions. Some integrative and longevity medicine clinics build senolytic protocols into their programs, usually as cash pay services, since insurers typically do not cover experimental longevity supplements.
Bottom Line
Evidence grade: Early. Fisetin has a plausible mechanism, strong data in aged mice showing senolytic activity and extended lifespan, and thin, still-developing human evidence. It may appeal to healthy adults who understand they are experimenting with an unproven longevity compound. It is not appropriate as a treatment, and it is a poor fit for anyone on medication, pregnant, or expecting proven benefits. Main limitations: poor bioavailability, unknown optimal human dose, and no long-term human safety or efficacy data. Promising biology, unproven in people.
The next real data point is the AFFIRM program: both Mayo Clinic trials list an estimated primary completion in November 2026 [4][5]. Until results are published, treat any confident fisetin claim, positive or negative, as ahead of the evidence.
Related reading
Sources
- Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: a dietary antioxidant for health promotion. Antioxid Redox Signal. 2013. PMID 23121441 ↩
- Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018. DOI 10.1016/j.ebiom.2018.09.015 (PMID 30279143) ↩
- Zhu Y, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors A1331852 and A1155463. Aging (Albany NY). 2017. PMID 28273655 ↩
- Mayo Clinic. Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (AFFIRM). ClinicalTrials.gov. NCT03430037 ↩
- Mayo Clinic. Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults. ClinicalTrials.gov. NCT03675724 ↩
- Fisetin and Neurodegeneration: From Preclinical Studies to Potential Clinical Applications. 2026. PMID 42227472 ↩
Medical disclaimer: This article is for general educational purposes only and is not medical advice. Fisetin is not an approved treatment for any condition. Do not start, stop, or change any supplement or medication based on this content. Consult a qualified healthcare professional before using high-dose fisetin, especially if you take medication, are pregnant or breastfeeding, or have a medical condition.
